Tralokinumab + TCS

Phase 3Monoclonal antibody

LEO Pharma

Tralokinumab + TCS is one of 27 small molecule programs targeting Atopic Dermatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atopic DermatitisActive, not recruiting

Atopic DermatitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

508 competitors in Atopic Dermatitis

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

1 2

Nereus

VVanda Pharmaceuticals

Phase 3

3 3

Elidel

Bayer

Phase 3

4 4

LNK01001

LLynk Pharmaceuticals Co., Ltd

Phase 3

2 5

EBGLYSS

Eli Lilly

Preclinical

23 6

Cibinqo

Pfizer

Preclinical

11 7

OPA-15406

Otsuka

Phase 3

7 8

Ketotifen Fumarate

Tanabe Pharma Corporation

Phase 3

1 9

Product 0405

FFougera Pharmaceuticals Inc.

Phase 3

3 10

Prograf

VVeloxis Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Recruiting

Atopic Dermatitis

NCT06311682

Clinical

Trials by Indication[1]

Atopic Dermatitis1 trial

A Phase 3 Multi-center Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children (Age 2 to <12 Years) and Infants (Age 6 Months to <2 Years) With Moderate-to-severe Atopic Dermatitis. The Trial is Randomized, Double-blind, Placebo-controlled, and Parallel-group for Children (Age 2 to <12 Years) and Open-label and Single-group for Infants (Age 6 Months to <2 Years)

Recruiting· LEO Pharma logo

LEO Pharma·Phase 3·NCT06311682·195 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tralokinumab + TCS. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tralokinumab + TCS compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tralokinumab + TCS. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — LEO Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: LEO Pharma

Tralokinumab + TCS

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Atopic Dermatitis1 trial

References

Drug Info

Quick Facts

Related News